Stockreport

Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF Sotagliflozin, in Combination with Insulin, Significantly Decreased A1C Levels and Reduced Weight at 52 Weeks Results Observed at 24 Weeks Persisted at 52 Weeks TH [Read more]